| pubmed-article:17869503 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17869503 | lifeskim:mentions | umls-concept:C0005522 | lld:lifeskim |
| pubmed-article:17869503 | lifeskim:mentions | umls-concept:C0282635 | lld:lifeskim |
| pubmed-article:17869503 | lifeskim:mentions | umls-concept:C0376432 | lld:lifeskim |
| pubmed-article:17869503 | lifeskim:mentions | umls-concept:C0184511 | lld:lifeskim |
| pubmed-article:17869503 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:17869503 | pubmed:dateCreated | 2007-11-23 | lld:pubmed |
| pubmed-article:17869503 | pubmed:abstractText | Plants may serve as superior production systems for complex recombinant pharmaceuticals. Current strategies for improving plant-based systems include the development of large-scale production facilities as well as the optimisation of protein modifications. While post-translational modifications of plant proteins generally resemble those of mammalian proteins, certain plant-specific protein-linked sugars are immunogenic in humans, a fact that restricts the use of plants in biopharmaceutical production so far. The moss Physcomitrella patens was developed as a contained tissue culture system for recombinant protein production in photo-bioreactors. By targeted gene replacements, moss strains were created with non-immunogenic humanised glycan patterns. These were proven to be superior to currently used mammalian cell lines in producing antibodies with enhanced effectiveness. | lld:pubmed |
| pubmed-article:17869503 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17869503 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17869503 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17869503 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17869503 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17869503 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:17869503 | pubmed:issn | 0958-1669 | lld:pubmed |
| pubmed-article:17869503 | pubmed:author | pubmed-author:ReskiRalfR | lld:pubmed |
| pubmed-article:17869503 | pubmed:author | pubmed-author:DeckerEva LEL | lld:pubmed |
| pubmed-article:17869503 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17869503 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:17869503 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17869503 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17869503 | pubmed:pagination | 393-8 | lld:pubmed |
| pubmed-article:17869503 | pubmed:meshHeading | pubmed-meshheading:17869503... | lld:pubmed |
| pubmed-article:17869503 | pubmed:meshHeading | pubmed-meshheading:17869503... | lld:pubmed |
| pubmed-article:17869503 | pubmed:meshHeading | pubmed-meshheading:17869503... | lld:pubmed |
| pubmed-article:17869503 | pubmed:meshHeading | pubmed-meshheading:17869503... | lld:pubmed |
| pubmed-article:17869503 | pubmed:meshHeading | pubmed-meshheading:17869503... | lld:pubmed |
| pubmed-article:17869503 | pubmed:meshHeading | pubmed-meshheading:17869503... | lld:pubmed |
| pubmed-article:17869503 | pubmed:meshHeading | pubmed-meshheading:17869503... | lld:pubmed |
| pubmed-article:17869503 | pubmed:meshHeading | pubmed-meshheading:17869503... | lld:pubmed |
| pubmed-article:17869503 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17869503 | pubmed:articleTitle | Moss bioreactors producing improved biopharmaceuticals. | lld:pubmed |
| pubmed-article:17869503 | pubmed:affiliation | Plant Biotechnology, Faculty of Biology, University of Freiburg, Schaenzlestr. 1, D-79104 Freiburg, Germany. | lld:pubmed |
| pubmed-article:17869503 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17869503 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:17869503 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
